Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vivos Therapeutics, Inc. filings document its OSA-focused medical device and healthcare services business, including reported operating results, sleep testing services, the integration of The Sleep Center of Nevada assets and treatment revenue from supported OSA care locations.
The company’s 8-K and related disclosures also cover material financing agreements, warrant exercises, private placements, convertible note terms, resale-registration references, board and committee appointments, annual-report timing and Nasdaq continued-listing compliance tied to stockholders’ equity. These filings describe common stock, warrants and other capital-structure instruments alongside governance and risk-related public-company matters.
Vivos Therapeutics reports first-quarter 2026 revenue of $5.1M, up from $3.0M a year earlier, driven mainly by higher sleep testing and treatment center service revenue. Despite this growth, the company posted a net loss of $7.8M, widening from $3.9M. Operating cash outflow was $6.0M, leaving cash and equivalents at $2.1M against total liabilities of $26.3M and an accumulated deficit of about $133M. Management states that existing cash will not fund operations for the next twelve months, and substantial doubt exists about the company’s ability to continue as a going concern without additional financing. The quarter also reflects integration of the 2025 Sleep Center of Nevada acquisition, which added service revenue but has not yet offset the higher costs and debt taken on for the deal.
Vivos Therapeutics, Inc. notified the SEC it cannot timely file its Form 10-Q for the quarter ended March 31, 2026 and submitted a Form 12b-25 requesting the five-calendar-day extension under Rule 12b-25. The company states its independent auditor and management need additional time to review and consolidate interim financial statements from its SCN acquisition before filing.
The company currently expects to file within the five-day extension. It also reports preliminary operating direction: revenue and gross profit each rose (approximately 70% and 100%, respectively) for the three months ended March 31, 2026 versus the prior-year quarter; SG&A expenses increased about 70%, and net loss is expected to increase. These figures remain under review and may differ in the Form 10-Q.
Vivos Therapeutics, Inc. — Armistice Capital, LLC and Steven Boyd jointly report beneficial ownership of 1,115,859 shares of Common Stock, representing 8.27% of the class as reported with an as‑of date of 03/31/2026. The filing states Armistice Capital exercises shared voting and dispositive power over these shares on behalf of the Master Fund, and the submission is signed by Steven Boyd as Managing Member.
Vivos Therapeutics, Inc. registers 3,964,712 shares of Common Stock for resale, consisting of 1,982,356 shares issuable upon exercise of a five-year Series A Warrant and 1,982,356 shares issuable upon exercise of a 24‑month Series B Warrant. The resale is by a selling stockholder; the company will not receive proceeds from sales but may receive proceeds if the Warrants are exercised for cash.
The prospectus states the Warrants were issued in a January 20, 2026 warrant inducement private placement and that the selling stockholder may sell shares at prevailing market prices, through brokers or negotiated transactions, at its sole discretion. The filing discloses the Company will bear registration expenses and that as of May 7, 2026 the last reported sale price was $0.66 per share; there were 13,714,329 shares outstanding as of that date.
Vivos Therapeutics, Inc. registers 3,964,712 shares of Common Stock issuable upon exercise of two private-placement warrants (1,982,356 shares under a five-year Series A Warrant and 1,982,356 shares under a 24-month Series B Warrant).
This prospectus covers resale by the selling stockholder and states the company will not receive proceeds from sales by the selling stockholder, although the company may receive proceeds if the Warrants are exercised for cash. The filing describes the warrants’ $2.09 exercise price, Nasdaq listing (VVOS), recent last sale price of $0.85 per share (April 28, 2026), and context on the company’s pivot to a medical-provider focused MSO/DSO model and its integration of The Sleep Center of Nevada.
Vivos Therapeutics received a Nasdaq notice on April 17, 2026 that its stockholders’ equity reported in its 2025 annual report does not meet Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million of stockholders’ equity. As of December 31, 2025, the company reported negative stockholders’ equity of about $1.55 million.
Vivos has since completed two equity financings in the first quarter of 2026 for total gross proceeds of $6.8 million, showing it can raise capital, though this alone does not cure the deficiency. The company has until June 1, 2026 to submit a compliance plan and could receive up to October 14, 2026 to regain compliance, but there is no assurance its plan will be accepted or that it will meet the requirement, and a delisting would materially harm its operations and reputation.
Vivos Therapeutics reported full-year 2025 results with higher revenue but sharply wider losses and a weakened balance sheet. Revenue rose to $17.5 million from $15.0 million, a 16% increase, driven mainly by more sleep testing services and treating obstructive sleep apnea patients at two Nevada locations of The Sleep Center of Nevada, which Vivos acquired in June 2025.
Gross profit increased to $10.5 million from $9.0 million and gross margin held at 60%. However, operating expenses climbed to $30.4 million from $20.2 million, reflecting integration and management costs for The Sleep Center of Nevada and related treatment centers, leading to an operating loss of $19.9 million versus a $11.2 million loss in 2024. Net loss widened to $21.2 million.
Cash and cash equivalents declined to $2.0 million as of December 31, 2025, from $6.3 million a year earlier, while current debt reached $8.4 million. Total liabilities rose to $26.7 million and total equity moved from positive $8.0 million to a deficit of $1.6 million. Management highlighted a strategic pivot away from enrolling VIP dentists toward alliances and acquisitions of sleep specialty providers and reiterated its goal of achieving cash flow positive operations by the end of the year.
Vivos Therapeutics reported full-year 2025 results with higher revenue but sharply wider losses and a weakened balance sheet. Revenue rose to $17.5 million from $15.0 million, a 16% increase, driven mainly by more sleep testing services and treating obstructive sleep apnea patients at two Nevada locations of The Sleep Center of Nevada, which Vivos acquired in June 2025.
Gross profit increased to $10.5 million from $9.0 million and gross margin held at 60%. However, operating expenses climbed to $30.4 million from $20.2 million, reflecting integration and management costs for The Sleep Center of Nevada and related treatment centers, leading to an operating loss of $19.9 million versus a $11.2 million loss in 2024. Net loss widened to $21.2 million.
Cash and cash equivalents declined to $2.0 million as of December 31, 2025, from $6.3 million a year earlier, while current debt reached $8.4 million. Total liabilities rose to $26.7 million and total equity moved from positive $8.0 million to a deficit of $1.6 million. Management highlighted a strategic pivot away from enrolling VIP dentists toward alliances and acquisitions of sleep specialty providers and reiterated its goal of achieving cash flow positive operations by the end of the year.
Vivos Therapeutics, Inc. files its annual report describing a major pivot from a legacy dentist-focused distribution model to a medical-provider focused strategy built around sleep centers and managed service organizations. The company acquired The Sleep Center of Nevada (SCN) in June 2025 and is integrating its seven locations into the Vivos platform.
SCN generated $4.8 million of diagnostic revenue and $2.0 million of treatment revenue in 2025, and Vivos plans to scale operations using dedicated Sleep Optimization teams. Management highlights substantial risks, including a history of operating losses, the need for additional capital, integration and regulatory challenges, and dependence on insurance reimbursement and acceptance of The Vivos Method.
Vivos Therapeutics, Inc. files its annual report describing a major pivot from a legacy dentist-focused distribution model to a medical-provider focused strategy built around sleep centers and managed service organizations. The company acquired The Sleep Center of Nevada (SCN) in June 2025 and is integrating its seven locations into the Vivos platform.
SCN generated $4.8 million of diagnostic revenue and $2.0 million of treatment revenue in 2025, and Vivos plans to scale operations using dedicated Sleep Optimization teams. Management highlights substantial risks, including a history of operating losses, the need for additional capital, integration and regulatory challenges, and dependence on insurance reimbursement and acceptance of The Vivos Method.
V-Co Investors 3 LLC, a ten percent owner of Vivos Therapeutics, Inc., filed an initial ownership report on Form 3. It reports direct holdings of 1,353,625 shares of Common Stock, plus a Pre-Funded Warrant for 429,957 underlying shares at $0.0001 per share, and Series A and Series B Common Stock Warrants each covering 1,783,582 underlying shares at an exercise price of $1.09 per share. The Series A warrant expires on March 31, 2028 and the Series B warrant on March 31, 2031, while the Pre-Funded Warrant runs until fully exercised.